Sosei Group (JP:4565) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nxera Pharma has commenced a Phase 3 clinical trial in South Korea to evaluate its insomnia treatment, daridorexant, following its recent approval in Japan. Insomnia affects a significant portion of South Korea’s population, and this trial aims to provide further efficacy and safety data to secure marketing authorization in the country. The trial underscores Nxera’s commitment to addressing insomnia’s serious health impact and expanding its market reach in Asia.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.